Sakar Healthcare Ltd

Sakar Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sakar Healthcare Ltd

₹ 328 0.31%
26 Jul - close price
Company website NSE: SAKAR
About

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

Key Points

Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.

Website NSE
  • Market Cap ₹ 714 Cr.
  • Current Price ₹ 328
  • High / Low ₹ 479 / 249
  • Stock P/E 61.2
  • Book Value ₹ 121
  • Dividend Yield 0.00 %
  • ROCE 7.53 %
  • ROE 5.36 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 2.72 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 8.24% over last 3 years.
  • Promoter holding has decreased over last 3 years: -20.9%
  • Working capital days have increased from 31.5 days to 62.5 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
21.68 30.26 31.64 29.74 36.59 28.53 30.71 33.47 40.65 38.99 34.08 37.23 43.06
14.61 23.77 24.55 23.09 27.41 20.57 22.12 24.67 32.87 29.96 24.72 28.22 32.09
Operating Profit 7.07 6.49 7.09 6.65 9.18 7.96 8.59 8.80 7.78 9.03 9.36 9.01 10.97
OPM % 32.61% 21.45% 22.41% 22.36% 25.09% 27.90% 27.97% 26.29% 19.14% 23.16% 27.46% 24.20% 25.48%
0.41 0.27 0.75 0.27 0.88 0.41 0.60 1.85 1.81 1.52 0.66 0.23 0.77
Interest 0.43 0.49 0.79 0.94 0.68 0.86 0.99 1.94 2.15 2.08 1.65 1.79 2.08
Depreciation 4.82 2.18 1.68 2.62 3.19 3.57 3.77 4.10 3.55 4.52 4.22 4.44 4.87
Profit before tax 2.23 4.09 5.37 3.36 6.19 3.94 4.43 4.61 3.89 3.95 4.15 3.01 4.79
Tax % 22.42% 10.51% 54.19% 96.43% -45.56% 26.90% 56.21% 13.02% -0.77% 28.10% 12.53% 30.90% 34.86%
1.74 3.65 2.46 0.11 9.01 2.88 1.94 4.01 3.92 2.84 3.64 2.07 3.12
EPS in Rs 1.11 2.13 1.44 0.06 5.26 1.68 1.04 2.15 2.06 1.49 1.70 0.95 1.43
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
22 30 35 41 44 53 68 83 95 128 133 153
14 22 27 33 34 40 51 63 72 99 100 115
Operating Profit 8 8 8 8 10 13 17 20 23 29 33 38
OPM % 34% 26% 22% 20% 23% 24% 25% 24% 24% 23% 25% 25%
0 0 0 0 1 0 1 2 1 2 4 3
Interest 4 4 3 3 3 3 2 2 2 3 6 8
Depreciation 2 2 2 3 3 4 6 7 8 10 15 18
Profit before tax 2 2 2 3 5 6 9 12 13 19 17 16
Tax % 19% 13% 24% 22% 30% 38% 28% 21% 19% 20% 24% 27%
1 2 2 2 3 4 7 10 11 15 13 12
EPS in Rs 1.81 2.19 2.30 2.78 3.08 3.12 4.47 6.43 6.84 8.90 6.70 5.37
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 18%
5 Years: 18%
3 Years: 17%
TTM: 15%
Compounded Profit Growth
10 Years: 21%
5 Years: 12%
3 Years: 3%
TTM: -9%
Stock Price CAGR
10 Years: %
5 Years: 41%
3 Years: 23%
1 Year: 28%
Return on Equity
10 Years: 10%
5 Years: 9%
3 Years: 8%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 8 8 8 8 11 12 15 15 16 17 19 22
Reserves 4 6 7 11 25 35 57 66 83 110 154 241
27 24 25 22 24 11 11 17 43 93 119 69
11 14 11 10 11 23 15 17 37 47 44 57
Total Liabilities 50 52 50 51 71 81 97 115 178 268 336 389
37 38 36 37 49 53 64 66 69 205 267 314
CWIP 0 0 0 0 0 0 9 13 49 1 6 0
Investments 0 0 0 0 0 0 0 0 0 7 3 0
13 14 14 14 22 28 25 36 60 55 60 74
Total Assets 50 52 50 51 71 81 97 115 178 268 336 389

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
7 9 4 9 2 5 16 19 15 36 33 24
-3 -3 -1 -4 -14 -8 -25 -22 -47 -90 -74 -52
-7 -6 -3 -6 13 -13 9 3 32 55 41 27
Net Cash Flow -4 -0 1 -1 0 -16 0 -0 -0 -0 0 0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 22 28 21 26 44 74 51 36 48 40 60 50
Inventory Days 281 190 142 107 114 51 70 92 112 69 76 121
Days Payable 109 97 20 66 51 57 41 46 141 149 129 120
Cash Conversion Cycle 194 120 143 67 107 68 80 83 19 -39 7 51
Working Capital Days 155 75 89 45 110 108 46 41 8 2 30 62
ROCE % 14% 15% 14% 14% 15% 15% 16% 16% 13% 12% 9% 8%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
67.54% 67.54% 67.54% 67.54% 62.10% 62.10% 60.72% 60.72% 54.15% 53.15% 53.15% 53.15%
0.00% 0.00% 0.00% 0.00% 16.12% 16.12% 15.74% 15.74% 14.03% 13.76% 13.52% 13.52%
8.76% 8.76% 8.76% 8.76% 0.55% 0.33% 0.00% 0.00% 10.82% 10.62% 10.62% 10.62%
23.70% 23.70% 23.70% 23.70% 21.24% 21.45% 23.54% 23.54% 21.00% 22.47% 22.71% 22.71%
No. of Shareholders 6,4816,5426,7026,0915,6786,2106,3226,0567,2997,0017,3867,313

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Oct 2022
    Transcript
    Notes
    PPT